



DIHYDROIMIDAZOBENZOTHIADIAZINE DIOXIDES **

Richard Friary * and Elijah H. GoldChemical Research, Schering Corporation,
Bloomfield, New Jersey 07003, U.S.A.

Reductive cyclization of 2-methylthio-1-(2-nitrobenzenesulfonyl)-4,5-dihydroimidazolides gave a series of 1H-2,3-dihydroimidazo[1,2-b][1,2,4]benzothiadiazine 5,5-dioxides, three of which were isomerized by potassium iodide to 3H-1,2-dihydroimidazo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxides.


A variety of heteropolycyclic compounds whose structures embody a guanidine group has been reported to lower blood pressure;¹ among these are 3-alkylamino[1,2,4]benzothiadiazine 1,1-dioxides (e.g., 1) and tetrahydroimidazo[2,1-b]quinazolines (e.g., 2).^{2,3}



** Dedicated to Professor R.B. Woodward for the sixtieth anniversary of his birthday.


Prompted by an interest in hypertensive therapy, we have prepared two series (Tables 1 and 2) of compounds in one of which the sulfonyl group of the former (1) is embedded in the tricyclic array of the latter (2).

Table 1. 1H-2,3-Dihydroimidazo[1,2-b][1,2,4]benzothiadiazine 5,5-Dioxides.⁴



No.	Substituents			Mp (°C)
	R ¹	R ²	R ³	
3	H	H	H	256-7
4	H ₂ N	H	H	278-9
5	MeO	H	H	313-6
6	MeO	MeO	H	290-1
7	H	NO ₂	H	304-7
8	Cl	Cl	H	310-3
9	H	H	Me	134-6

Table 2. 3H-1,2-Dihydroimidazo[2,1-c][1,2,4]benzothiadiazine 5,5-Dioxides.⁴




No.	Substituents			Mp (°C)
	R ¹	R ²	R ³	
10	H	H	H	342-9
11	H	H	Me	297-8
12	Cl	Cl	Ac	320-5
13	H	H	Ac	300-5

The availability⁵ and the structures of 2-nitrobenzenesulfonyl chlorides suggested combination of them with 2-methylthio-2-imidazoline, reduction of the nitro group of the resulting nitrobenzenesulfonyl-dihydroimidazolides, and cyclization to the

tricyclic compounds by elimination of methanethiol from the expected aminobenzenesulfonyl-dihydroimidazolides. Certain nitrobenzenesulfonyl-dihydroimidazolides were prepared, and, as expected, underwent reductive cyclization (SnCl_2 , HCl ;⁶ HOAc , MeOH).

Table 3. Preparation of 1H-2,3-Dihydroimidazo-[1,2-b][1,2,4]benzothiadiazine 5,5-Dioxides.




Starting Material ⁴			Product	Yield (%)
<u>R¹</u>	<u>R²</u>	<u>Mp (°C)</u>		
H	H	185-6	<u>3</u>	92
NO_2	H	168-9	<u>4</u>	52
MeO	H	110-3	<u>5</u>	83
MeO	MeO	171-2	<u>6</u>	71


Reactions of methylthioimidazoline with 2-amino-5-nitrobenzenesulfonyl chloride, ⁷ and with 2-amino-4,5-dichlorobenzenesulfonyl chloride, ⁸ gave the corresponding aminobenzenesulfonyl-dihydroimidazolides. ⁹ Methanolic acetic acid converted these to 7 (59%) and 8 (74%), respectively.

Although compounds 3-8 behaved (mp, tlc, nmr) as single substances, they may be tautomeric, and therefore both N-methyl isomers of 3 were prepared for comparison. Methylation (NaH , DMF,

MeI) of 3 gave 60% of 9 and 14, mp 132-3°, ⁴ in a ratio of 20:1. Both isomers (9, 3%; 14, 1%) could also be obtained by treatment of 15 with trimethyl phosphite. Reaction of the anion of 3 and trimethyl phosphate, formed by initial deoxygenation ($\text{ArNO}_2 \rightarrow \text{ArNO}$), may account for the observed methylations. ¹⁰




Inspection of the structure of 3 suggested that, if the bond between C-3 and N-4 could be broken by a nucleophile, re-closure of the ambident anion [i] might yield the isomer 10. When 3 was heated with potassium iodide in hexamethylphosphoric triamide (HMPA) at 200°, 10 was obtained in a yield of 86%. To confirm the structural assignments, 10 was methylated (NaH, DMF, MeI) to 11 (88%), and 9 was rearranged (75%) with iodide (HMPA, 200°) to the same (tlc, ir, nmr) product (11).







Cyclization (Ac_2O , Py, CHCl_3) of crude 2-methylthio-1-(2-amino-4,5-dichlorobenzenesulfonyl)-4,5-dihydroimidazolidine (16) ⁹ gave (73%) an N-acetyldihydroimidazo[1,2-b][1,2,4]benzothiadiazine dioxide, mp 221-4°, ^{4,11} which was isomerized with iodide in dimethylacetamide at 166° to 12 (88%). For comparison, 10 was

acetylated (Ac_2O , Py) to 13 (86%).



The assignments of structures to 3-9 and 14 are based on comparisons of their uv spectra and of their nmr spectra with those of model compounds, 17-20.³ The similarities of the uv spectra and chemical shifts of the C-2 and C-3 protons imply that, in solution, 3¹³ and 9¹⁴ are structurally alike. The similar chemical shifts of 14¹⁵ and 18, which (18) was prepared unambiguously,³ show they are related as illustrated. The downfield shift ($\nu\delta = +0.54\text{ppm}$) of the N-methyl group of 14 contrasted to that of 9 allows assignment of their structures and those of 3-8 as shown. Deshielding of a nearby methyl group, planar with a benzene ring, can also be observed in 20 contrasted to 19.³



No.	R ¹	R ²	R ³
<u>21</u>	H	Me	Me
<u>22</u>	Me	Me	Me
<u>23</u>	Ac	Me	Me
<u>24</u>	Ac	Ph	H
<u>25</u>	Ac	Ph	Me

26, R=H
27, R=Me

The structures of 10-13¹⁶ were established by comparisons of their uv spectra with those of models 21-23.¹⁷ The results of methylation of 26 ($\rightarrow$ 27, 21, and 22), and of methylation of 24 ($\rightarrow$ 25), suggest that alkylation at sulfonyl-bound nitrogen is disfavored in such systems; in this sense, these results precedent the outcomes of methylation of 10 and of the rearrangements observed in the present work.^{17,18}

ACKNOWLEDGEMENT

We thank the staff of Analytical Research Services of Schering Corporation for microanalyses, ir, nmr, uv, and mass spectra; we are grateful to Professor Sir D.H.R. Barton for suggesting the rearrangement of 3 to 10.

REFERENCES AND NOTES

- 1 R.P. Mull and R.A. Maxwell, 'Antihypertensive Agents,' ed. E. Schlittler, Academic Press, New York, 1967, p. 114.
- 2 L. Raffa, M. Di Bella, P. Ferrari, and M. Rinaldi, Il Farmaco (Sci.), 1974, 29, 417.
- 3 T. Jen, B. Dienel, H. Bowman, J. Petta, A. Helt, and B. Loev, J. Med. Chem., 1972, 15, 727.
- 4 Each new compound for which a mp is reported gave acceptable ($\pm 0.4\%$) microanalytical values and showed the expected value of m/e for M^+ in its medium-resolution mass spectrum.
- 5 J.G. Topliss, M.H. Sherlock, H. Reimann, L.M. Konzelman, E.P. Shapiro, B.W. Pettersen, H. Schneider, and N. Sperber, J. Med. Chem., 1963, 6, 122.
- 6 R.B. Woodward, Org. Syn., Coll. Vol. III, ed. E.C. Horning, John Wiley & Sons, Inc., New York, 1955, p. 453.
- 7 J.R. Bartels-Kelth and R.W. Cieciuch, Can. J. Chem., 1963, 46, 2593.
- 8 J.H. Short and U. Biermacher, J. Am. Chem. Soc., 1960, 82,

1135.

9 These intermediates were not characterized, but were cyclized without purification.

10 J.I.G. Cadogan, Quart. Rev., 1968, 22, 2.

11 Because of a lack of unequivocal models, ¹² the structure of this derivative could not be assigned by ordinary spectral measurements.

12 The N-1 acetyl structure of the product of acetylation of 1H-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-5-one may be correct, but its assignment resulted from misinterpretation of a differential chemical shift. ³ The $\nu\delta$ -value of 0.4ppm (CDCl₃), attributed to anisotropy of the acetyl carbonyl, ³ may be calculated from the data of Ref. 3 on the premiss of additivity of substituent effects.

13 $\lambda_{\max}$ (EtOH) 265 (4.25), 306 (3.74)nm; δ (DMSO) 3.62 (m, 2H₂), 4.08 (m, 2H₃)ppm.

14 $\lambda_{\max}$ (EtOH) 270 (4.43), 307 (3.94)nm; δ (DMSO) 2.95 (s, NCH₃), 3.59 (m, 2H₂), 4.02 (m, 2H₃); (CDCl₃) 2.99, 3.48, 4.02ppm.

15 $\lambda_{\max}$ (EtOH) 260 (4.36), 301 (3.57)nm; δ (DMSO) 3.52 (s, NCH₃), 3.88 (s, 2H₂ and 2H₃); (CDCl₃) 3.53, 3.98 (s, 2H₂ and 2H₃)ppm.

16 $\lambda_{\max}$ (MeOH) :: 10 : 250 (4.09), 290 (3.28); 11 : 253 (4.17), 292 (3.28); 12 : 272 (4.08); 13 : 264 (3.16)nm.

17 J.G. Topliss and L.M. Konzelman, J. Org. Chem., 1963, 28, 2313.

18 Compounds 3-14 were devoid of hypotensive activity.

Received, 29th August, 1977